Is avatrombopag (Sucoxin) suitable for patients with leukemia and thrombocytopenia?

Avatrombopag is an oral, small-molecule thrombopoietin receptor (TPO-R) agonist that stimulates the production and maturation of megakaryocytes in the bone marrow, thereby promoting platelet production. The drug is currently approved primarily for the treatment of thrombocytopenia in patients with chronic liver disease before surgery or invasive procedures, and for the long-term management of patients with chronic immune thrombocytopenia (ITP). However, its indications do not cover leukemia-related thrombocytopenia, because the bone marrow function of patients with leukemia is occupied by malignant cells, and the mechanism of platelet production impairment is more complex.

Thrombocytopenia in patients with leukemia is mostly caused by a large number of tumor cells infiltrating the bone marrow and inhibiting normal hematopoiesis. Chemotherapy drugs will also further suppress bone marrow function. This type of thrombocytopenia is not due to thrombopoietin deficiency but to an impairment of the hematopoietic microenvironment. Therefore, relying solely on TPO receptor agonists to stimulate platelet production often has limited efficacy and may even stimulate the growth of malignant cells. Some studies have shown that the use of avatrombopag in patients with leukemia may lead to activation of the TPO receptor pathway in leukemia cells, posing a potential risk of disease progression.

Currently, there are very few clinical studies on avatrombopag in leukemia-related thrombocytopenia, and there is insufficient evidence to support its safe and effective use. A small number of case reports suggest that short-term use of this drug by individual patients in remission after chemotherapy can temporarily increase platelet levels, but it cannot fundamentally improve the myelosuppression state, and platelets often drop rapidly after drug withdrawal. Therefore, international guidelines generally do not recommend the use of avatrombopag or other TPO agonists as routine treatment in patients with leukemia, except under strict monitoring and as a temporary adjuvant regimen in special cases.

Taken together, avatrombopag is not suitable for routine treatment of thrombocytopenia in patients with leukemia. For such patients, the first choice should be to actively control the leukemia itself, optimize the chemotherapy regimen, and provide supportive treatments, such as platelet transfusions and the use of leukemia-enhancing drugs to improve bone marrow function. If the patient is in remission and has persistent thrombocytopenia, a short-term trial can be carefully considered after risk assessment under the guidance of a hematologist. Overall, the application prospects of avatrombopag in patients with leukemia still need to be verified by more clinical data, and safety should still be the primary consideration at present.

Reference materials:https://www.drugs.com/